FIELD: biotechnology, enzymes.
SUBSTANCE: invention relates to modified gelonin enzyme and method for production thereof. Claimed method includes identification of antigen regions in enzyme by using antibody, removing of at least one antigen region and determination of fermentative activity of obtained modified gelonin enzyme. Also disclosed is multipeptide protein compound based on modified gelonin enzyme added to the second polypeptide such as antibody, toxin or other enzyme and having decreased antigenicity. Also disclosed is humanized recombinant toxin gelonin (HRTG) with decreased antigenicity and amino acid sequence wherein at least three amino acid residues from one or more 1,2,3, or 4 antigenic domains are substituted with other amino acid residues. HRTG, modified gelonin enzyme, and multipeptide protein compound are useful as drug for therapy of cancer.
EFFECT: modified proteins with decreased antigenicity and high cytotoxicity in relates to tumor cells, in particular myeloma cells.
27 cl, 11 dwg, 9 tbl, 6 ex
